Trade Name(s)

  • Zioptan

Ther. Class.

ocular hypotensive agent

Pharm. Class.



Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic Effect(s):

↓ intraocular pressure.


Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.

Distribution: Unknown.

Metabolism and Excretion: Further metabolized and eliminated.

Half-life: Unknown.

TIME/ACTION PROFILE (↓ in intraocular pressure)

Ophthwithin 2–4 hr12 hr24 hr


Contraindicated in:

  • Pedi:  Avoid use in children due to unknown safety of chronic ↑ pigmentation.

Use Cautiously in:

  • Aphakia, pseudoaphakia with a torn posterior lens capsule
  • Known risk factors for macular edema
  • OB:  Women with child-bearing potential should practice adequate contraception
  •  Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

EENT: conjunctival hyperemia, blurred vision, cataract, permanent iris pigmentation, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Note noted.


Ophth:  (Adults): One drop once daily (into conjunctival sac) in the evening into affected eye(s).


Ophthalmic solution : 0.0015% in 0.3 mL single-use containers


  • Measure intraocular pressure periodically during therapy.

Potential Diagnoses


  • Ophth:  

    Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.

    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the  Patient Information Leaflet  prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

Reduction of intraocular pressure.

tafluprost is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. .